Business
Voyageur Pharmaceuticals Ltd. Announces Issuance of Shares for Debt
(TheNewswire) Calgary, AB - TheNewswire - January 27, 2023 - Voyageur...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"Voyageur Pharmaceuticals Ltd. Announces Issuance of Shares for Debt\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Calgary,\n \n \n AB\n \n \n -\n \n \n TheNewswire -\n \n \n January 27, 2023 -\n \n \n Voyageur Pharmaceuticals Ltd.\n \n \n (TSXV:VM)\n \n \n (USA:VYYRF)\n \n \n (the\n\"\n \n \n Company\n \n \n \" or \"\n \n \n Voyageur\n \n \n \") announces that, further to its\nnews release dated December 2, 2022, it has issued a total of 125,322\nCommon Shares at a deemed price of $0.09974 per Common Share for\npayment of outstanding debts of $12,500 owed to former directors of\nthe Company and the outstanding debts have now been extinguished.\n \n \n \n \n The Common Shares issued by the Company have a hold\nperiod of four months and one day from the date of issuance in\naccordance with applicable securities legislation.\n \n \n \n \n About Voyageur\n \n \n \n \n Voyageur is a Canadian public company listed on the\nTSXV under the trading symbol VM. Voyageur is focused on the\ndevelopment of barium and iodine Active Pharmaceutical Ingredients\n(“API”) and high-performance cost-effective imaging contrast\nagents for the medical imaging marketplace. Voyageur’s goal is to\nfully integrate the barium and iodine contrast market by producing its\nown minerals of barium and iodine. The business plan is to initially\ngenerate cash flow from operations using third party GMP\npharmaceutical manufacturers in Canada and validate the products for\nregulatory agencies globally. Then transitioning into a high margin\ndomestic manufacturer of radiology drugs. Voyageur has plans to build\ncarbon neutral infrastructure to become 100% self-sufficient across\nall manufacturing activities. Voyageur owns a 100% interest in three\nbarium sulphate (barite) projects including the Frances Creek\nproperty, suitable in grade for the pharmaceutical marketplace, with\nadditional interests in a high-grade iodine, lithium & bromine\nbrine project located in Utah, USA. Voyageur is moving forward with\nits business plan of becoming the only fully integrated carbon neutral\ncompany in the radiology contrast media drug market, by controlling\nall primary input costs under the motto of:\n \n \n \n \n \"From the Earth to the\nBottle\".\n \n \n \n \n For Further Media\nInformation or to set up an...